Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis
Authors' conclusion
A higher serum sCXCL16 level was identified as a predictive biomarker of RPILD in patients with DM, and closely associated with poor prognosis.
Study context
- Population
- Patients with dermatomyositis (DM) and matching healthy donors
- Participants
- 96 / 31 / 55
- Comparison
- DM vs matched healthy donors; DM with rapidly progressive interstitial lung disease (RPILD); high vs low sCXCL16
- DMn = 96
- DM with RPILDn = 31
- Healthy donorsn = 55reference
- Outcome
- Serum sCXCL16 level and its predictive value for RPILD
Methodological detailscase-control with matched healthy donors, ELISA, multivariable analysis
- Case-control with matched healthy donors
- ELISA
- Multivariable analysis
Main finding
As reported in the abstract
Serum sCXCL16
Observational data: associations, not effects.
Further findings
Correlations of sCXCL16
- Positively correlated with ferritin, CRP, ESR, LDH, hydroxybutyrate dehydrogenase; negatively with peripheral lymphocyte %; no correlation with anti-MDA5, KL-6 or creatine kinase
2-year survival, high vs low sCXCL16
- Significantly lower in high sCXCL16 than low sCXCL16
Original publication
Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis. Semin Arthritis Rheum. Published 31 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →